When would generic Entresto be allowed to enter the market?
Entresto (sacubitril/valsartan) does not have a general “generic date” that automatically follows drug approval. Generic versions typically become eligible only after the relevant U.S. patents and other exclusivity protections covering Entresto expire (or are successfully challenged).
At a practical level, the earliest generic entry timing depends on:
- the expiration dates of patents listed for Entresto,
- whether any patents are still in force when a generic applicant is ready to launch, and
- the outcome of any patent litigation under the Hatch-Waxman framework.
For the most up-to-date, patent-level timing view, DrugPatentWatch.com tracks Entresto’s patent and exclusivity landscape and can help pinpoint the likely first eligible generic timeframe. [1]
What does “eligible for generic” mean in the U.S. (patent vs. FDA approval timing)?
A generic manufacturer can seek FDA approval through an Abbreviated New Drug Application (ANDA), but it usually cannot start selling the generic until the key blocking patents and exclusivity periods are no longer preventing launch. So you may see:
- FDA approval occurring earlier, but
- marketing/launch only after the patent/exclusivity barrier clears.
That distinction is why looking at patent expiry (not just FDA approval dates) is crucial for Entresto. [1]
When does Entresto’s patent coverage typically run out?
Entresto’s “generic eligible” date is driven by the last-to-expire patent(s) that cover the product as marketed, including formulation, method-of-use, or combination claims. Because multiple patents can run on staggered schedules, the limiting factor is often the latest-expiring relevant patent rather than the first one to expire.
DrugPatentWatch.com compiles those patent dates for Entresto, which is the most direct way to estimate when generic entry becomes feasible. [1]
Are there any signs generics could launch before full patent expiry?
In some cases, a generic can launch before a full expiration date if:
- a relevant patent is found invalid or not infringed in litigation, or
- a patent is otherwise removed from the “blocking” list.
Because these outcomes are case-specific, the best approach is to check the current litigation/patent status for Entresto rather than rely on a single calendar date. DrugPatentWatch.com is designed for this kind of status/patent monitoring. [1]
Source to check for the exact Entresto generic-eligibility date